Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc.

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$55.78 -0.41 (-0.73%) At close · Sep 30
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.79B
Shares
153.07M
Volume · Sep 30 1.91M Avg daily vol (3M) 2.05M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$55.78 Open$56.41 Day$55.36–56.98 52W close$26.94–59.06 Avg vol 30d1.9M Short int30.2M · 19.7% float · 18.5d Short vol75% Last earningsAug 3, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 1, 2026 Est · unconfirmed · in 4 wks
Latest filing: 10-Q
filed Aug 5, 2026
Q2 2026 earnings call transcript
call held Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$799.54M
Trailing 12 months
Net income (TTM)
$441.49M
Trailing 12 months
Revenue growth YoY
+70.3%
Year over year
Operating margin
17.1%
Trailing 12 months
P / E (TTM)
20.5
Trailing earnings · reciprocal yield 4.9%
FCF yield
0.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.2%
Year over year · fewer shares
Price change (1Y)
+52.6%
Trailing year
Short interest
19.7%
Latest settlement · 18.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +36%
above
Price vs 50-day avg +4%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 90%
near high
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +61%
trailing
YTD return +87%
this year
Relative strength +49%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $54 › 200d $41 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +108 funds added
Insider flow Distributing
Net -$274.8K over 90 days · 100% sells
Short interest Rising
19.70% of float · ▲ +0.1% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
438 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Fair
Revenue growth −58%
Y/Y
EPS growth +1747%
Y/Y
Free cash flow $-25.0M
Valuation P/E 21
in line
Buyback $400.0M
authorized
Balance sheet $7.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2026
full year 2026
Total global revenue Initiated $950M
prior FY $616.29M midpoint +54.1% Y/Y
Full year OPEX excluding stock-based compensation Non-GAAP Initiated $350M – $400M
fourth quarter 2026
Quarterly U.S. net revenue at least $250M
full year
OPEX, excluding stock-based compensation $350M – $400M
Guided vs delivered · last 1 settled
Net revenues full year 2022
guided $50M – $75M
$2.79M Miss −95.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+36% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
90% Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $54 › 200d $41 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +108 funds added
Insider flow Distributing
Net -$274.8K over 90 days · 100% sells
Short interest Rising
19.70% of float · ▲ +0.1% MoM · 18.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
438 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27 Now $56 · 90% Range high $59
vs 200-day avg +36% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TGTX
Tg Therapeutics, Inc.
this stock
$8.79B +87.1% -58.4% 21.0 19.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
438
% held
75.2%
Net QoQ
+5.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
333
View
Short & Settlement
Short Interest Rising
Shares short
30.2M
Days to cover
18.5d
Change
+24.8K sh
View
Short Volume
Short vol %
75%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
12.6K
Value
$704.9K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
44.0%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$274.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Sep 8, 2020
View
Financials
Financials
Revenue (FY)
$616.3M
Net income (FY)
$447.2M
EPS diluted
$2.77
View
Buybacks
Authorized · 2 programs
$400.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
15
View
Proposed Sales
Value
$274.8K
Shares
5.0K
Filed
Sep 10, 2026
View
Earnings & Events
Earnings Calls
Last call
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
TGTX -0.4% -0.6% +61.1% +2.7% +87.1%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +0.3% -0.7% +48.9% +3.3% +75.3%

Capital returns

Buyback programs · 2 active · as of Jun 30, 2026
Authorized (total)
$400.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 11 filings 11 filers Visit website Investor relations